Jefferies initiates buy on Krystal Biotech with a $245 price target, citing Vyjuvek's strong growth potential and proprietary ...

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy ...

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...

EC approval decision anticipated in second quarter of 2025PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, ...

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) rose 7.1% during mid-day trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup ...

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...